Literature DB >> 17923792

Prognostic value of International Diabetes Federation and Adult Treatment Panel III definitions of metabolic syndrome in Type 2 diabetic patients: what makes the difference?

M Monami1, N Marchionni, G Masotti, E Mannucci.   

Abstract

AIM: The International Diabetes Federation (IDF) proposed new diagnostic criteria for metabolic syndrome (MS), lowering glucose and waist thresholds, and rendering abdominal adiposity necessary for diagnosis. In Type 2 diabetic patients, IDF-defined MS has a lower prognostic value than Adult Treatment Panel III (ATP-III) criteria; this could depend either on lower thresholds for waist, or on the fact that adiposity was made necessary for diagnosis.
METHODS: Information on 3-yr all-cause mortality of a consecutive series of 882 Caucasian Type 2 diabetic outpatients was obtained by the City of Florence Registry Office. Two different modifications of ATP-III criteria were tested: low waist threshold (LWT), with same threshold as IDF, but with abdominal adiposity not considered a necessary condition; and elevated waist as necessary condition (EWNC), with the older ATP-III threshold.
RESULTS: Over the follow-up period, 115 (13.6%) deaths were recorded. A significantly higher mortality rate was observed in patients with LWT-, but not EWNC-defined MS, in comparison with the rest of the sample (14.2% vs 13.3%, p=0.705, and 14.7% vs 8.9%, p=0.050, for EWNC and LWT, respectively). Lowering the waist threshold did not reduce prognostic value in comparison with ATP-III definition of MS; conversely, when elevated waist circumference was considered a necessary condition for diagnosis, the predictive value for mortality decreased, irrespective of thresholds used.
CONCLUSION: In Type 2 diabetic patients, modification of thresholds for waist circumference does not alter the prognostic value of MS. However, if abdominal adiposity is considered a necessary condition for diagnosis, the ability of MS to predict all-cause mortality is markedly reduced.

Entities:  

Mesh:

Year:  2007        PMID: 17923792     DOI: 10.1007/BF03347441

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  25 in total

1.  Proteinuria and metabolic syndrome as predictors of cardiovascular death in non-diabetic and type 2 diabetic men and women.

Authors:  A Juutilainen; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  Diabetologia       Date:  2005-12-20       Impact factor: 10.122

2.  Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes.

Authors:  R N Guzder; W Gatling; M A Mullee; C D Byrne
Journal:  Diabetologia       Date:  2005-12-10       Impact factor: 10.122

3.  The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.

Authors:  Trevor J Orchard; Marinella Temprosa; Ronald Goldberg; Steven Haffner; Robert Ratner; Santica Marcovina; Sarah Fowler
Journal:  Ann Intern Med       Date:  2005-04-19       Impact factor: 25.391

4.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

5.  Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study.

Authors:  Martin K Rutter; James B Meigs; Lisa M Sullivan; Ralph B D'Agostino; Peter W Wilson
Journal:  Diabetes       Date:  2005-11       Impact factor: 9.461

6.  Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study.

Authors:  Graziella Bruno; Franco Merletti; Annibale Biggeri; Giuseppe Bargero; Stefania Ferrero; Cristina Runzo; Stefano Prina Cerai; Gianfranco Pagano; Paolo Cavallo-Perin
Journal:  Diabetes Care       Date:  2004-11       Impact factor: 19.112

Review 7.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Richard Kahn; John Buse; Ele Ferrannini; Michael Stern
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

8.  Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study.

Authors:  Jacqueline M Dekker; Cynthia Girman; Thomas Rhodes; Giel Nijpels; Coen D A Stehouwer; Lex M Bouter; Robert J Heine
Journal:  Circulation       Date:  2005-08-02       Impact factor: 29.690

9.  IDF and ATP-III definitions of metabolic syndrome in the prediction of all-cause mortality in type 2 diabetic patients.

Authors:  M Monami; N Marchionni; G Masotti; E Mannucci
Journal:  Diabetes Obes Metab       Date:  2007-05       Impact factor: 6.577

10.  The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study.

Authors:  E Bonora; G Targher; G Formentini; F Calcaterra; S Lombardi; F Marini; L Zenari; F Saggiani; M Poli; S Perbellini; A Raffaelli; L Gemma; L Santi; R C Bonadonna; M Muggeo
Journal:  Diabet Med       Date:  2004-01       Impact factor: 4.359

View more
  1 in total

Review 1.  Hypogonadism and metabolic syndrome.

Authors:  G Corona; G Rastrelli; A Morelli; L Vignozzi; E Mannucci; M Maggi
Journal:  J Endocrinol Invest       Date:  2011-06-27       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.